Narrow-Spectrum Antibiotics Face Clinical Trial Design Hurdles, Panel Says
Executive Summary
Study protocols have to take into account the broad-spectrum antibacterial therapy that seriously ill patients are likely to receive while awaiting confirmation of the specific pathogenic cause of infection, which can take many hours or days with current diagnostic methods.